TAK-448

**TAK‑448** is an investigational synthetic oligopeptide analog of kisspeptin, specifically designed as a potent agonist of the G protein-coupled receptor 54 (GPR54), also known as the kisspeptin receptor or KISS1R[3][4][6]. It mimics the fully active C-terminal region of endogenous kisspeptin and acts by stimulating KISS1R. Acute administration stimulates luteinizing hormone (LH) and follicle-stimulating hormone release; however, continuous subcutaneous exposure rapidly downregulates the pituitary-gonadal axis, leading to a rapid reduction in testosterone levels in a dose-dependent manner[4][5]. This mechanism underlies its development for androgen deprivation therapy in prostate cancer and for conditions related to hypogonadotropic hypogonadism. In preclinical models and early clinical trials, TAK‑448 demonstrated potent antitumor activity through suppression of androgen hormones and direct inhibition of tumor cell proliferation[7]. The drug was developed by Takeda.

Other names

TAK448TAK-448TAK 448MVT-602MVT602MVT 602L-Tryptophanamide, N-acetyl-D-tyrosyl-(4R)-4-hydroxy-L-prolyl-L-asparaginyl-L-threonyl-L-phenylalanyl-2-azaglycyl-L-leucyl-N5-(imino(methylamino)methyl)-L-ornithyl-(D-Tyr46,D-pya-(4)47,azagly51,arg-(me)53)-metastin-(46–54)